Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. more
Time Frame | EQ | Sector | S&P500 |
---|---|---|---|
1-Week Return | -11.04% | 0.31% | -1.26% |
1-Month Return | 7.62% | 0.6% | -4.16% |
3-Month Return | -20.88% | -9.44% | -0.46% |
6-Month Return | -22.61% | -5.15% | 3.58% |
1-Year Return | -20.76% | 0.33% | 22.47% |
3-Year Return | -81.23% | 4.53% | 25.13% |
5-Year Return | -85.22% | 35.98% | 77.7% |
10-Year Return | -95.08% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | 15.76M | 36.08M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":43.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 23.00K | 45.00K | 72.00K | 118.00K | 126.00K | [{"date":"2019-12-31","value":18.25,"profit":true},{"date":"2020-12-31","value":35.71,"profit":true},{"date":"2021-12-31","value":57.14,"profit":true},{"date":"2022-12-31","value":93.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (23.00K) | (45.00K) | (72.00K) | 15.64M | 35.96M | [{"date":"2019-12-31","value":-0.06,"profit":false},{"date":"2020-12-31","value":-0.13,"profit":false},{"date":"2021-12-31","value":-0.2,"profit":false},{"date":"2022-12-31","value":43.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | 99.25% | 99.65% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":99.6,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 26.73M | 29.55M | 37.79M | 54.79M | 50.61M | [{"date":"2019-12-31","value":48.78,"profit":true},{"date":"2020-12-31","value":53.93,"profit":true},{"date":"2021-12-31","value":68.97,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.37,"profit":true}] |
Operating Income | (26.73M) | (29.55M) | (37.79M) | (62.08M) | (14.52M) | [{"date":"2019-12-31","value":-2672700000,"profit":false},{"date":"2020-12-31","value":-2954800000,"profit":false},{"date":"2021-12-31","value":-3778600000,"profit":false},{"date":"2022-12-31","value":-6207600000,"profit":false},{"date":"2023-12-31","value":-1452200000,"profit":false}] |
Total Non-Operating Income/Expense | 2.24M | (888.00K) | (2.28M) | (985.00K) | 3.02M | [{"date":"2019-12-31","value":74.07,"profit":true},{"date":"2020-12-31","value":-29.37,"profit":false},{"date":"2021-12-31","value":-75.49,"profit":false},{"date":"2022-12-31","value":-32.58,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (25.60M) | (29.81M) | (39.05M) | (62.43M) | (12.76M) | [{"date":"2019-12-31","value":-2560000000,"profit":false},{"date":"2020-12-31","value":-2981300000,"profit":false},{"date":"2021-12-31","value":-3905200000,"profit":false},{"date":"2022-12-31","value":-6242800000,"profit":false},{"date":"2023-12-31","value":-1275500000,"profit":false}] |
Income Taxes | (23.00K) | (45.00K) | (72.00K) | 45.28M | 580.00K | [{"date":"2019-12-31","value":-0.05,"profit":false},{"date":"2020-12-31","value":-0.1,"profit":false},{"date":"2021-12-31","value":-0.16,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":1.28,"profit":true}] |
Income After Taxes | (25.58M) | (29.77M) | (38.98M) | (107.71M) | (13.34M) | [{"date":"2019-12-31","value":-2557700000,"profit":false},{"date":"2020-12-31","value":-2976800000,"profit":false},{"date":"2021-12-31","value":-3898000000,"profit":false},{"date":"2022-12-31","value":-10770700000,"profit":false},{"date":"2023-12-31","value":-1333500000,"profit":false}] |
Income From Continuous Operations | (25.60M) | (29.81M) | (39.11M) | (62.43M) | (8.22M) | [{"date":"2019-12-31","value":-2560000000,"profit":false},{"date":"2020-12-31","value":-2981300000,"profit":false},{"date":"2021-12-31","value":-3911100000,"profit":false},{"date":"2022-12-31","value":-6242800000,"profit":false},{"date":"2023-12-31","value":-822000000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (25.58M) | (29.77M) | (38.98M) | (107.71M) | (13.34M) | [{"date":"2019-12-31","value":-2557700000,"profit":false},{"date":"2020-12-31","value":-2976800000,"profit":false},{"date":"2021-12-31","value":-3898000000,"profit":false},{"date":"2022-12-31","value":-10770700000,"profit":false},{"date":"2023-12-31","value":-1333500000,"profit":false}] |
EPS (Diluted) | (1.48) | (1.49) | (1.35) | (1.18) | (0.39) | [{"date":"2019-12-31","value":-148,"profit":false},{"date":"2020-12-31","value":-149,"profit":false},{"date":"2021-12-31","value":-135,"profit":false},{"date":"2022-12-31","value":-118,"profit":false},{"date":"2023-12-31","value":-39,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
EQ | |
---|---|
Cash Ratio | 2.34 |
Current Ratio | 3.04 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
EQ | |
---|---|
ROA (LTM) | -11.95% |
ROE (LTM) | -33.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
EQ | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.33 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.67 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
EQ | |
---|---|
Trailing PE | NM |
Forward PE | 1.53 |
P/S (TTM) | 0.57 |
P/B | 1.06 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.07 |
Equillium Inc (EQ) share price today is $0.6888
Yes, Indians can buy shares of Equillium Inc (EQ) on Vested. To buy Equillium Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in EQ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Equillium Inc (EQ) via the Vested app. You can start investing in Equillium Inc (EQ) with a minimum investment of $1.
You can invest in shares of Equillium Inc (EQ) via Vested in three simple steps:
The 52-week high price of Equillium Inc (EQ) is $3.25. The 52-week low price of Equillium Inc (EQ) is $0.56.
The price-to-earnings (P/E) ratio of Equillium Inc (EQ) is
The price-to-book (P/B) ratio of Equillium Inc (EQ) is 1.06
The dividend yield of Equillium Inc (EQ) is 0.00%
The market capitalization of Equillium Inc (EQ) is $24.40M
The stock symbol (or ticker) of Equillium Inc is EQ